This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Colorado Kids Get Legal Pot as New York Doctors Can Barely Study It

NEW YORK (TheStreet) -- Doctors are increasingly frustrated about federal marijuana restrictions standing in the way of important research.

"It is troubling that while few barriers exist for parents to give their children marijuana in Colorado, there are significant federal roadblocks preventing doctors from studying it in a rigorous scientific manner," write Orrin Devinsky and Daniel Friedman, physicians at the Comprehensive Epilepsy Center at New York University in The New York Times Wednesday.

The two doctors voiced skepticism about many of the perceived medical benefits of marijuana, and argued that "the recent wave of state legislatures considering and often approving medical marijuana raises significant concerns."

At the same time, however, they state that the government's classification of marijuana as a "schedule 1" drug places severe restrictions on their ability to study the effects of its active ingredients, including the chemical compounds cannabidiol, or CBD, and tetrahydrocannabinol, or THC. 

Must Read: Whole Foods Plunges: What Wall Street's Saying

"While it is possible to study Schedule 1 drugs in a controlled laboratory setting, it is extremely difficult to study these substances in patients. For our study, we keep the CBD in a 1,200-pound safe in a locked room, in a building with an alarm system," the doctors write.

:

Similar frustration came through in an article in the latest issue of The New York Review of Books by Harvard Medical School Professor Jerome Groopman, a longtime staff writer for The New Yorker magazine.

While Groopman's article tended more toward information than opinion, he appeared to be more excited than the NYU doctors about the potential medical benefits from marijuana and related drugs. Still, he wrote that as a physician prescribing therapy for patients, he is in "an uncomfortable situation," since even in the 20 states where medical marijuana is legal, it "is regulated like a supplement rather than a drug," with "no standardization of optimal amounts of psychoactive THC and nonpsychoactive CBD."

Proposed legislation, including a bill introduced Wednesday by Steve Cohen (D.-Tenn.) would ease restrictions on medical research involving marijuana.

And Cohen was one of 18 members of Congress who sent a letter to President Obama Wednesday urging him to remove marijuana from the list of schedule I and II drugs. Marijuana is currently a schedule I drug, meaning federal laws regard it as more dangerous than cocaine, which is schedule II. The state and party affiliation of the signers, however, allude to the significant political obstacles to marijuana liberalization at the federal level. Seventeen signers are Democrats and only one, California Rep. Dana Rohrabacher, is a Republican.

Follow @dan_freed

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AAPL $111.79 3.80%
FB $89.76 2.90%
GOOG $612.05 2.40%
TSLA $246.96 3.50%
YHOO $31.67 0.22%

Markets

Chart of I:DJI
DOW 16,313.57 +255.22 1.59%
S&P 500 1,937.79 +23.94 1.25%
NASDAQ 4,717.8620 +81.7570 1.76%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs